N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-oxo-butanoyl]-hydroxy-amino]pentyl]-N'-(5-aminopentyl)-N'-hydroxy-butanediamide; zinc

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-oxo-butanoyl]-hydroxy-amino]pentyl]-N'-(5-aminopentyl)-N'-hydroxy-butanediamide; zinc
• 英文别名: N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentyl]-N'-(5-aminopentyl)-N'-hydroxybutanediamide;zinc
• 化学式: C25H48N6O8Zn
• 分子量: 626.1
• InChiKey: CVFIJKNFGHQIFM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.92
• 重原子数：
  40
• 可旋转键数：
  23
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  206
• 氢给体数：
  6
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  、 甲磺酸去铁敏 、 氯化锌 生成 N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-oxo-butanoyl]-hydroxy-amino]pentyl]-N'-(5-aminopentyl)-N'-hydroxy-butanediamide; zinc
  参考文献：
  名称：

  Pharmaceutical compositions containing a zinc complex

  摘要：

  该发明提供了一种药物组合物，其中包含一种以去铁胺或青霉胺的锌络合物为活性成分，与药理学上可接受的载体相结合。

  公开号：

  US05075469A1

文献信息

• Method and pharmaceutical composition for treatment of neurodegeneration
  申请人：Chevion Mordechai

  公开号：US11033630B2

  公开（公告）日：2021-06-15

  The present invention provides pharmaceutical compositions comprising a metal-desferrioxamine B complex or a combination thereof, for preventing, inhibiting, reducing or ameliorating neurodegeneration, thereby treating diseases, disorders, or conditions characterized by or associated with neurodegeneration; as well as methods of use.

  本发明提供了包含金属-去铁胺 B 复合物或其组合的药物组合物，用于预防、抑制、减轻或改善神经变性，从而治疗以神经变性为特征或与之相关的疾病、失调或病症；以及使用方法。
• ARTIFICIAL DNA-BINDING PROTEINS AND USES THEREOF
  申请人：Fondazione Telethon

  公开号：EP3071592B1

  公开（公告）日：2021-01-06
• ECTOPICALLY EXPRESSED TRANSCRIPTION FACTORS AND USES THEREOF
  申请人：Università di Napoli Federico II

  公开号：EP3728599A1

  公开（公告）日：2020-10-28
• COMPOSITIONS AND METHODS FOR TREATMENT OF DEMYELINATION
  申请人：Chevion, Mordechai

  公开号：EP3773535A1

  公开（公告）日：2021-02-17
• EYE DROPS TO TREAT CHEMICALLY INDUCED CORNEAL DAMAGE
  申请人：MOHAN RAJIV R.

  公开号：US20210128526A1

  公开（公告）日：2021-05-06

  Provided herein are compositions suitable for treating chemically induced eye damage comprising (a) a nonsteroidal anti-inflammatory drug (NSAID), (b) a histone deacetylase (HDAC) inhibitor and (c) an angiotensin converting enzyme (ACE) inhibitor and, optionally, (d) a water-soluble vitamin. Methods of using provided compositions to treat ocular toxicity and corneal damage following exposure to chemical agents (e.g., mustard gas) are also provided.